Baxter To Distribute Ceprate During Cellpro Bankruptcy Until Isolex Approval
This article was originally published in The Gray Sheet
Executive Summary
Baxter will distribute Cellpro's Ceprate stem cell concentration system worldwide pending approval of Nexell's Isolex stem cell collection system under a bankruptcy plan for CellPro.
You may also be interested in...
Nexell To Use Peer-Reviewed Articles To Demonstrate Cytonex Diagnostic Use
Nexell Therapeutics plans to use studies published in peer-reviewed journal articles to support marketing efforts for its Cytonex immunocytochemistry (ICC) staining kit for in vitro diagnostic use.
Nexell To Use Peer-Reviewed Articles To Demonstrate Cytonex Diagnostic Use
Nexell Therapeutics plans to use studies published in peer-reviewed journal articles to support marketing efforts for its Cytonex immunocytochemistry (ICC) staining kit for in vitro diagnostic use.
Baxter, Cerus Platelet Viral Inactivation System Enters Phase III Trial
Baxter's Fenwal Division plans to manufacture, market and distribute a system intended to inactivate viruses, bacteria and other pathogens in platelet concentrations.